top of page
gwave_monitoring_free.jpg

Non-invasive Glucose Monitoring

Accidental Discovery

GWave is the world's first non-invasive glucometer, which offers a disruptive solution utilizing radio frequency (RF) waves to continuously measure glucose levels in the blood. 


The revolutionary concept was conceived by GWave’s CTO and Co-founder, Dr. Geri Waintraub, when he accidently spilled a cup of tea on an RF device during  routine experimentation for an RF research initiative.
He immediately noticed that the sugar in the tea caused the dramatic reaction on the system’s monitors.
 
Following the serendipitous spill, Dr. Waintraub began formulating ideas about the enormous applications the technology could have toward helping hundreds of millions of people with diabetes worldwide.
GWave’s technology was developed into a prototype that yielded a successful POC with astonishing results that meet the FDA guidelines. 

רקע מחשב תגלית שחור לבן.png
כוס מחשב.png
Discovery
Technology

Our Technology

Utilizes RF Wave technology that monitors glucose levels in the blood continuously and in real-time. User safety is our foremost priority, using significantly less radiation than a smartphone.

GWave’s  sensors are developed with propriety AI algorithms that enables GWave to be cost-efficient, compact, and capable of delivering impeccably accurate measurements. 

app.png

Our App

Our device seamlessly connects to Bluetooth and smartphones, creating a painless, straightforward and pleasant user experience.

Users can track their glucose readings as frequently and repeatedly as needed.
The built-in automated alarm feature is a key benefit to ensure proper notification to the user of fluctuation in glucose levels.

Our Cloud

cloud.png

Our cloud securely stores all the user’s measurement data, and can deliver important information to caretakers and medical professionals. Our software is safe, secure, and reliable.

Our Accuracy

accuracy.png

Our device’s accuracy is over 95% when compared to an off-theshelf handheld finger-prick device.
With GWave’s innovative technology, glucose is monitored in the blood and not in the interstitial fluid. Monitoring the blood itself yields efficient and incredibly accurate results.

news

 Company News

HAGAR Unveils New Clinical Data on Groundbreaking GWave Technology, Closing Round C Funding

HAGAR, the startup behind GWave, a non-invasive continuous glucose monitoring system, successfully secured a $5 million Series C funding round, bringing its total funding to $25 million. The startup recently showcased its latest clinical findings at the 83rd Scientific Sessions of the American Diabetes Association (ADA).

HAGAR Announces Preliminary Results of Study For Its Non Invasive Glucose Monitoring System

Study Results Reveal Stellar Accuracy for HAGAR’s Second Generation Mass Produced Chip on the heels of its Series C Round

HAGAR GWave Awarded FDA Breakthrough Device Designation

HAGAR GWave Awarded FDA Breakthrough Device Designation Expediting Development of GWave technology that may potentially improve the health and quality of life for millions of diabetes patients

HAGAR Secures $11.7M Series B Funding to Advance Non-Invasive Blood Glucose Monitoring Technology

GWave 2.0 delivers accurate, affordable, and accessible continuous monitoring and testing for blood glucose, improving the quality of life for the global diabetes population

Hagar Noninvasive Glucometer Announces $4.4m Series A for World’s First Wearable, Non-Invasive Glucose Monitoring Device

GWave Technology to Improve Quality of Life for Millions of Diabetes Worldwide by Eliminating the Need for Painful, Inconvenient Finger Pricking Tests

In the Press

Press
diatribe-logo.png
Fierce-Biotech-Color (2)_250x190.png
Fortune_magazine_logo_2016.svg.png
302-3024814_bloomberg-logo-vector-clipart.png
cropped-g-medtech_logo.jpg
mddi+.png
diatribe-logo.png
Fierce-Biotech-Color (2)_250x190.png
Fortune_magazine_logo_2016.svg.png
cropped-g-medtech_logo.jpg
mddi+.png
302-3024814_bloomberg-logo-vector-clipart.png
Team

Senior Management

guy.jpg

General Guy Zur

Co-Founder, CEO

General Zur joined the IDF in 1983 and served in the military until 2016 in a variety of positions retiring with the rank of Major General.

benzi.jpg

Br. General Bentzi Gruber (res)

Co-Founder, Chairman

Br. General Gruber (res) has served on the board of numerous investment funds and companies which include over 15 years experience

gerry.jpg

Dr. Gerry Vaintrub

Co-Founder, CTO

Dr. Vaintrub, holds a PhD. in physics and electronics and has over 30 years’ experience in developing electronic systems for multi-market segments

taire.jpg

Taire Rubin

Co-founder and VP of Business Development

Taire has extensive experience leading business development, capital funding and marketing teams with a variety of technology companies

Maor-site.jpg

Maor Zur

COO

Maor’s creativity and expert organizational skills has attributed to her ability to multi-task, run variety of administrative needs and seamlessly bring together multiple initiatives

Advisory Board

irl-hirsh.jpg

Dr. Irl Hirsch

Medical Advisor, US

Dr. Hirsch received his medical degree from the University of Missouri School of Medicine in 1984. He completed residency training in internal medicine at the University of Miami

moshe.jpg

Dr. Moshe Rubin

Medical Advisor, Israel

Dr. Moshe Rubin is an Associate Professor of Clinical Medicine at Weill-Cornell Medical College and a Physician Leader with extensive administrative and medical device industry experience.

Alexander FLEMING.jpg

Alexander Fleming, M.D.

Medical and Regulatory Advisor, US

Dr. Alexander Fleming is Founder and Executive Chairman of Kinexum, a company of professionals from across the world with diverse expertise in developing drugs, biotech products, medical devices.

CONTACT

Get in Touch

Thanks for submitting!

bottom of page